Skip to main content
. 2017 Jul 24;8(33):55374–55383. doi: 10.18632/oncotarget.19520

Figure 2. Therapeutic efficacy of Doc and Abi in patients with or without IDC-P.

Figure 2

(A1, A2 and A3) Comparison of PSA response, PSA-PFS and OS between IDC-P(+) patients treated with Abi or Doc; (B1, B2 and B3) Comparison of PSA response, PSA-PFS and OS between IDC-P(–) patients treated with Abi or Doc.